A multicenter retrospective study using 18F-FDG-PET/CT for the prediction of immunotherapy-related interstitial lung disease in lung cancer.

A retrospective study using 18F-FDG-PET/CT for the prediction of immunotherapy-related interstitial lung disease in lung cancer. - A retrospective study using 18F-FDG-PET/CT for the prediction of immunotherapy-related interstitial lung disease in lung cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056876

Enrollment

200

Registered

2025-01-30

Start date

2025-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or recurrent lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with advanced stage or recurrent lung cancer who received ICIs during January 1, 2021 to December 31, 2023 in the following facilities. (2) FDG-PET/CT was taken within three months before ICI therapy. Participating facilities: Niigata University Hospital, Hokkaido Cancer Center, Tohoku University Hospital, Juntendo University Hospital, St. Marianna University Hospital, Kyoto Prefectural University of Medicine

Exclusion criteria

Exclusion criteria: (1) FDG uptake on lung region was difficult to evaluate owing to massive consolidation or pleural effusion (2) Patients with bilateral multiple primary lung cancers.

Design outcomes

Primary

Measure	Time frame
Interstitial lung disease after administration of immune checkpoint inhibitors	—

Secondary

Measure	Time frame
Onset of any adverse event after administration of immune checkpoint inhibitors Prognosis after administration of immune checkpoint inhibitors	—

Countries

Japan

Contacts

Public ContactSatoshi Watanabe

Niigata University Medical and Dental Hospital Department of Respiratory Medicine and Infectious Diseases

satoshi7@med.niigata-u.ac.jp025-368-9325

Outcome results